CompletedPhase 2NCT02107261
Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Studying Focal, segmental or multifocal dystonia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Principal Investigator
- Steven Frucht, MDNYU Langone Health
- Intervention
- incobotulinumtoxin A(drug)
- Enrollment
- 21 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2014 – 2020
Study locations (2)
- NYU Langone Health, New York, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Collaborators
Merz North America, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02107261 on ClinicalTrials.govOther trials for Focal, segmental or multifocal dystonia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07304089A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated DystoniaVima Therapeutics
- RECRUITINGNANCT05095740Effects of Neuromodulation in Laryngeal DystoniaMGH Institute of Health Professions
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02911103Deep Brain Stimulation Surgery for Focal Hand DystoniaNational Institute of Neurological Disorders and Stroke (NINDS)
See all trials for Focal, segmental or multifocal dystonia →